{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:35:34Z","timestamp":1762673734048},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/qai.0b013e3181ae2eb9","type":"journal-article","created":{"date-parts":[[2009,7,20]],"date-time":"2009-07-20T07:32:57Z","timestamp":1248075177000},"page":"562-568","source":"Crossref","is-referenced-by-count":49,"title":["A Randomized Comparative Trial of Continued Zidovudine\/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate\/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals"],"prefix":"10.1097","volume":"51","author":[{"given":"Martin","family":"Fisher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme J","family":"Moyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Shahmanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Kingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Ewan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210131","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-8-20210131","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"R3-8-20210131","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","article-title":"Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.","volume":"15","author":"Duran","year":"2001","journal-title":"AIDS"},{"key":"R4-8-20210131","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction.","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-8-20210131","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00042560-200201010-00007","article-title":"Anaemia in HIV-infected patients receiving highly active antiretroviral therapy.","volume":"29","author":"Moore","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R6-8-20210131","first-page":"34","article-title":"The assessing patients preferred treatments (APPT-1) study.","volume":"14","author":"Moyle","year":"2003","journal-title":"Int J STD AIDS"},{"key":"R7-8-20210131","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1468-1293.2005.00287.x","article-title":"Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.","volume":"6","author":"Portsmouth","year":"2005","journal-title":"HIV Med"},{"key":"R8-8-20210131","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1468-1293.2008.00618.x","article-title":"Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.","volume":"9","author":"Maitland","year":"2008","journal-title":"HIV Med"},{"key":"R9-8-20210131","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/QAI.0b013e3181142d26","article-title":"Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.","volume":"45","author":"Dube","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-8-20210131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Pozniak AL, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R11-8-20210131","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"R12-8-20210131","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.qai.0000143599.64234.15","article-title":"Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.","volume":"38","author":"Shlay","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R13-8-20210131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0149-2918(04)90009-4","article-title":"Changes in haematological parameters and treatment efficacy during thymidine analog-based HAART: a meta-analysis of 6 prospective randomized, comparative studies.","volume":"26","author":"Moyle","year":"2004","journal-title":"Clin Ther"},{"key":"R14-8-20210131","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Carr A, et al; for the Mitochondrial Toxicity (MITOX) Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"R15-8-20210131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200305010-00004","article-title":"A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy.","volume":"33","author":"Moyle","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-8-20210131","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"R17-8-20210131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00126334-200305010-00005","article-title":"Randomized, controlled, 48-week study of switching stavudine and\/or protease inhibitors to combivir\/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.","volume":"33","author":"John","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R19-8-20210131","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e3181aa12d5","article-title":"A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir\/lamivudine or tenofovir\/emtricitabine in HIV-1-infected patients with virological suppression.","volume":"51","author":"Martinez","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-8-20210131","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"R22-8-20210131","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1016\/j.jinf.2004.08.031","article-title":"Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature.","volume":"51","author":"Malik","year":"2005","journal-title":"J Infect"},{"key":"R23-8-20210131","first-page":"357","article-title":"Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature.","volume":"15","author":"Quimby","year":"2005","journal-title":"AIDS Read"},{"key":"R24-8-20210131","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/01.qai.0000138983.45235.02","article-title":"Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.","volume":"37","author":"Jones","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R25-8-20210131","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00002030-199905280-00010","article-title":"Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group.","volume":"13","author":"Mocroft","year":"1999","journal-title":"AIDS"},{"key":"R26-8-20210131","first-page":"26","article-title":"Prevalence and correlates of anaemia in a large cohort of HIV-infected women. Womens interagency HIV study.","volume":"28","author":"Levine","year":"2001","journal-title":"J Acquired Immune Defic Syndr"},{"key":"R27-8-20210131","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1086\/338151","article-title":"Prevalence and cumulative incidence of and risk factors for anaemia in a multicenter cohort study of HIV-infected and -uninfected women.","volume":"34","author":"Semba","year":"2002","journal-title":"Clin Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200908150-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:25:04Z","timestamp":1618039504000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200908150-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181ae2eb9","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}